Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
C105 in multiple sclerosis with cognitive impairment
NCT00529581Phase 2Completed
- Sponsor
- Cognition Therapeutics, Inc.
- Start
- Nov 2006
- Primary completion
- Mar 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of levoamphetamine in cognitive impairment, sponsored by Cognition Therapeutics, Inc.. Started Nov 2006; status: completed.
02
Drugs
levoamphetamine
03
Conditions
cognitive impairment
Beyond the preview
Go deeper on NCT00529581.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00529581.